The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients
Open accessAbstract
The objective of this study was to examine the effectiveness of resveratrol in lowering blood glucose in the presence of standard antidiabetic treatment in patients with type 2 diabetes, in a randomized placebo-controlled double-blinded parallel clinical trial. A total of 66 subjects with type 2 diabetes were enrolled in this study and randomly assigned to intervention group which was supplemented with resveratrol at a dose 1 g/day for 45 days and control group which received placebo tablets. Body weight, blood pressure, fasting blood glucose, haemoglobin A1c, insulin, homeostatic assessments for insulin resistance, triglycerides, total cholesterol, low density lipoprotein, high density lipoprotein, and markers of liver and kidney damage were measured at baseline and after 45 days of resveratrol or placebo supplementation. Resveratrol treatment significantly decreased systolic blood pressure, fasting blood glucose, haemoglobin A1c, insulin, and insulin resistance, while HDL was significantly increased, when compared to their baseline levels. On the other hand, the placebo group had slightly increased fasting glucose and LDL when compared to their baseline levels. Liver and kidney function markers were unchanged in the intervention group. Overall, this study showed that resveratrol supplementation exerted strong antidiabetic effects in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320
McColl, E., Jacoby, A., Thomas, L., Soutter, J., Bamford, C., Steen, N., Thomas, R., Harvey, E., Garratt, A., & Bond, J. (2001) · Health Technology Assessment · doi:10.3310/hta5310 · Cited by 788
Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2364 · Cited by 688
Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Mikolás, E., Szijártó, I. A., Mérei, Á., Halmai, R., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511000316 · Cited by 678
Approved IFCC reference method for the measurement of HbA1c in human blood
Jeppsson, J.-O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., Miedema, K., Mosca, A., Mauri, P., Paroni, R., et al. (2002) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2002.016 · Cited by 655
Resveratrol and health—A comprehensive review of human clinical trials
Smoliga, J. M., Baur, J. A., & Hausenblas, H. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100143 · Cited by 594
Cited by
Antioxidant effects of resveratrol in the cardiovascular system
Xia, N., Daiber, A., Förstermann, U., & Li, H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13492 · Cited by 574
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Resveratrol for cancer therapy: Challenges and future perspectives
Ren, B., Kwah, M. X.-Y., Liu, C., Ma, Z., Shanmugam, M. K., Ding, L., Xiang, X., Ho, P. C.-L., Wang, L., Ong, P. S., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.001 · Cited by 495
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 487
Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
Xu, L., Li, Y., Dai, Y., & Peng, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.015 · Cited by 452
Biological Activities of Stilbenoids
Akinwumi, B., Bordun, K.-A., & Anderson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030792 · Cited by 373
Resveratrol and diabetes: from animal to human studies
Szkudelski, T., & Szkudelska, K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.013 · Cited by 354
Alam, S., Sarker, M. M. R., Sultana, T. N., Chowdhury, M. N. R., Rashid, M. A., Chaity, N. I., Zhao, C., Xiao, J., Hafez, E. E., Khan, S. A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.800714 · Cited by 349
Effect of resveratrol and pterostilbene on aging and longevity
Li, Y., Li, S., & Lin, C. (2018) · BioFactors · doi:10.1002/biof.1400 · Cited by 346
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Resveratrol and Its Effects on the Vascular System
Breuss, J. M., Atanasov, A. G., & Uhrin, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071523 · Cited by 328
Liu, K., Zhou, R., Wang, B., & Mi, M.-T. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.082024 · Cited by 323
Dietary polyphenols as antidiabetic agents: Advances and opportunities
Sun, C., Zhao, C., Guven, E. C., Paoli, P., Simal‐Gandara, J., Ramkumar, K. M., Wang, S., Buleu, F., Pah, A., Turi, V., et al. (2020) · Food Frontiers · doi:10.1002/fft2.15 · Cited by 305
The pharmacology of resveratrol in animals and humans
Park, E.-J., & Pezzuto, J. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.014 · Cited by 302
The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus
David, J. A., Rifkin, W. J., Rabbani, P. S., & Ceradini, D. J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/4826724 · Cited by 301
Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial
Cao, H., Ou, J., Chen, L., Zhang, Y., Szkudelski, T., Delmas, D., Daglia, M., & Xiao, J. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1492900 · Cited by 293
Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights
De Sá Coutinho, D., Pacheco, M. T., Frozza, R. L., & Bernardi, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061812 · Cited by 290
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Chachay, V. S., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore–Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, P. J., Ferguson, M., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.024 · Cited by 289
Torres, N., Guevara-Cruz, M., Velázquez-Villegas, L. A., & Tovar, A. R. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.010 · Cited by 273
Zhu, X., Wu, C., Qiu, S., Yuan, X., & Li, L. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0217-z · Cited by 196
“For instance, the daily administration of resveratrol at doses of 8 [30] and 50 mg [26] did not reveal beneficial effects on metabolic parameter, whereas administration of this drug at higher doses (300, 1000, and 1500 mg) [7, 24, 28] showed beneficial effects on glucose homeostasis.”
BackgroundBo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G. F., Cassader, M., & Gambino, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.010 · Cited by 146
Cardiovascular and antiobesity effects of resveratrol mediated through the gut microbiota
Bird, J. K., Raederstorff, D., Weber, P., & Steinert, R. E. (2017) · Advances in Nutrition · doi:10.3945/an.117.016568 · Cited by 136
Resveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135
“The same could apply to humans, which is supported by the fact that so far only clinical trials in overweight/obese participants [13,44] or T2D patients [43,46, 58,59] have found beneficial effects.”
BackgroundResultInfluentialAnton, S. D., Embry, C., Marsiske, M., Lu, X., Doss, H., Leeuwenburgh, C., & Manini, T. M. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.05.015 · Cited by 95
de Ligt, M., Bruls, Y. M. H., Hansen, J., Habets, M.-F., Havekes, B., Nascimento, E. B. M., Moonen-Kornips, E., Schaart, G., Schrauwen-Hinderling, V. B., van Marken Lichtenbelt, W., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.04.004 · Cited by 79
Christenson, J., Whitby, S. J., Mellor, D., Thomas, J., McKune, A., Roach, P. D., & Naumovski, N. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2016.0035 · Cited by 47
Resveratrol and Spirulina: Nutraceuticals that potentially improving cardiovascular disease
Wang, Y., Ocampo, M. F., Rodriguez, B., & Chen, J. (2020) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000129 · Cited by 8
Metadata
- Authors
- Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., Rekabpour, S. J., & Netticadan, T.
- Venue
- Evidence-Based Complementary and Alternative Medicine
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 1741-427X (ISSN-L)
- 1741-4288
- OpenAlex
- W2071062711
- Cited by
- 257
- References
- 40
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.